SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Globe Newswire•11/11/2026•16:05 ET
0
Key Highlights
- ➤$215.8 million cash, equivalents and short-term investments expected to fund operations through 2028
- ➤$24.3 million Q3 net loss, or $0.73 per share, versus $9.8 million loss
- ➤AVS acquired for approximately $13 million, securing scalable commercial IOL manufacturing capacity
- ➤Four-year BIM-IOL data showed 37% mean IOP reduction and 86% drop-free patients
- ➤BIM-DRS first implantations completed; preliminary safety and efficacy data expected in 2027
Expert Statements
Patrick Mooney, Chief Executive Officer of SpyGlass Pharma
“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability. In parallel, enrollment in our Phase 3 trials of the BIM-IOL System remains on track, and we have secured long-term commercial manufacturing supply of the IOL for the BIM-IOL System and have become a supplier of other world-class IOLs”
Patrick Mooney, Chief Executive Officer of SpyGlass Pharma
“We are pleased to announce that our BIM-DRS is now in the clinic, with successful implantations of the next-generation drug delivery system in glaucoma patients who have had prior cataract surgery.”
* Acquired Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatoprost Drug Pad-IOL System (BIM-IOL System) and accelerating premium IOL portfolio expansion capability.
* Announced groundbreaking four-year first-in-human (FIH) efficacy and safety follow-up data of the BIM-IOL System, with a 37% reduction in mean intraocular pressure (IOP) across all dose levels and 86% of patients remaining off all topical IOP-lowering drops.
Get started
Create a free account to read the full story.